ProCE Banner Activity

EV-302/KEYNOTE-A39: Phase III Trial of Enfortumab Vedotin + Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Conference Coverage
Slideset

In this randomized phase III trial, enfortumab vedotin plus pembrolizumab demonstrated statistically and clinically significant improvements in PFS and OS vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer. 

Released: October 30, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc